Preeclampsia is one of the most serious pregnancy - specific medical conditions affecting 3-
6% of all gestations. It remains a leading cause of maternal and fetal morbidity and mortality. The aetiology
of preeclampsia is not fully elucidated yet, although a huge progress has been made in its understanding
within the last decade. Numerous studies have provided compelling evidence that an excess
of some antiangiogenic molecules released by the placenta to maternal circulation, in particular
soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng) and decreased levels of proangiogenic
substances like placental growth factor (PlGF) and vascular endothelial growth factor A
(VEGF-A) play a key role in the pathogenesis of preeclampsia. In this review, we report recent knowledge
about possible predictive, diagnostic and therapeutic roles of these pro- and antiangiogenic biomarkers
as well as analyzed the background of their use in these fields. Discoveries in the area of circulating
factors of angiogenesis are exciting and give promising perspectives for future clinical management
of preeclampsia. Currently, it can be difficult, especially in developing countries due to high
cost of such studies.
Keywords: Preeclampsia, pregnancy, hypertension, angiogenic factors, VEGF, PlGF, sFlt-1, sEng.
Rights & PermissionsPrintExport